BCEL Live signaler | Maksimer profitt med Getagraph.com

KJøP 115481 min ago

@ $0.286

Utstedt: 14 feb 2024 @ 18:10

Avkastning: -68.46%

Forrige signal: feb 13 - 15:38

Forrige signal: Selg

Avkastning: 16.83 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 21:49):

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types...

Stats
Dagens volum	42 299.00
Gjennomsnittsvolum	564 453
Markedsverdi	3.58M
EPS	$0 ( 2024-04-03 )
Neste inntjeningsdato	( $-0.350 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.00300 (3.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Orwin John A	Buy	1	Series A Junior Preferred Stock
2024-04-01	Serafini Tito	Sell	20 788	Class A Common Stock
2023-09-01	Orwin John A	Sell	22 951	Class A Common Stock
2023-09-01	Serafini Tito	Sell	8 393	Class A Common Stock
2023-09-01	Courtney Phillips	Sell	7 061	Class A Common Stock

INSIDER POWER
26.23
Last 95 transactions
Buy: 4 455 146 \| Sell: 2 042 595

Atreca Inc Korrelasjon

10 Mest positive korrelasjoner
GETVV	0.975
ENG	0.934
KZR	0.92
DRCT	0.918
CTMX	0.917
PSTX	0.916
JAN	0.914
ALLK	0.911
DAWN	0.909
CKPT	0.908

10 Mest negative korrelasjoner
BNIXU	-0.916
STAY	-0.907
PT	-0.899
NVCN	-0.894
OPRA	-0.893
DSPG	-0.893
SGEN	-0.886
CCRC	-0.879
XLNX	-0.879
LFMD	-0.879

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Atreca Inc Økonomi

Annual	2022
Omsetning:	$770 000
Bruttogevinst:	$-6.31M (-819.61 %)
EPS:	$-2.35

FY	2022
Omsetning:	$770 000
Bruttogevinst:	$-6.31M (-819.61 %)
EPS:	$-2.35

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.95

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.70

Financial Reports:

No articles found.

Atreca Inc

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Sanntidsoppdatering for Atreca Inc [BCEL]

Upcoming Earnings Alert